Articles tagged with Metastasis
Researchers have identified a new prognostic factor in breast cancer patients, predicting early disease recurrence, metastasis, and patient survival. The absence of caveolin-1 in the stroma is strongly associated with more aggressive disease and reduced progression-free survival.
Research at Memorial Sloan Kettering Cancer Center identifies three genes mediating breast cancer's spread to the brain. COX2 and HB-EGF prime cells for entrance, while ST6GALNAC5 enables passage through the blood-brain barrier.
Researchers are developing a strategic approach to studying metastasis, targeting the molecular and cellular players that mediate changes at future sites of metastasis. This could lead to new cancer treatments that target each step along the metastatic pathway.
Notch1 contributes to lung fibrosis by increasing myofibroblasts, while SOCS-1 inhibits prostate cancer growth. TIP30 prevents lung cancer metastasis, and SPARC accelerates kidney disease progression. These findings highlight potential new therapeutic targets.
Innate Therapeutics' novel microparticle-based immune response modifier MIS416 significantly inhibited tumor growth and metastasis in lung and breast cancers. Administered as an adjunct to localized tumor irradiation, MIS416 demonstrated synergistic activity against recurrent lung tumors.
Researchers found that brain metastases subvert astrocytes, tricking them into protecting tumors and resisting chemotherapy. Surgery is effective when tumor removal is done intact, reducing the risk of cancer spreading to the spinal fluid.
Researchers at Johns Hopkins Medicine tracked how prostate cancer began in 33 men, finding a set of genetic defects in a single cell that differ for each person's cancer. The study suggests that common genetic patterns across metastatic sites indicate a single cell source.
Scientists at Heidelberg University Hospital have identified a previously unknown protein called SCAI that inhibits the movement and spread of tumor cells. The study suggests that SCAI could be an interesting starting point for research into new mechanisms for fighting cancer.
Researchers at Mayo Clinic have discovered the molecular interplay that enables invasive tumor cells to move and invade other parts of the body. By manipulating this process, they hope to develop treatments to stop cancer from spreading.
Researchers identify TMEM density as key to predicting distant organ metastasis in breast cancer. The new marker could enable custom-tailored therapies and prevent over- or under-treatment.
The University of Texas M. D. Anderson Cancer Center has launched a new graduate program focusing on understanding and attacking cancer metastasis. The program, supported by a highly competitive grant from the University of Texas System, aims to improve basic understanding of cancer spread mechanisms.
Researchers at UVA Health System found that SRC gene promotes growth suppression in bladder cancer, contradicting its role in most cancers. The study suggests caution when using targeted therapeutic agents that inhibit SRC in bladder cancer treatment.
A new test for metastasis could help doctors precisely identify which patients should receive aggressive therapy, sparing those at low risk from unnecessary treatment. The test detects the presence of a tumor microenvironment that predicts breast cancer spread.
Researchers propose a new model explaining how cancer cells grow and spread, attributing inefficiency to pressure differences between tumor cells and host tissues. Understanding this process is crucial for developing effective treatments for metastatic cancer.
Researchers have identified a master protein that maintains epithelial cell normality and prevents cancer cells from metastasizing. The Epithelial Splicing Regulatory Protein (ESRP) plays a crucial role in regulating gene splicing, and its dysregulation can lead to cancer cell migration and tissue fibrosis.
Researchers created a mouse model of melanoma that replicates the earliest stages of skin cancer in humans. Testing two drug therapies caused a statistically significant regression in cancer cell development, offering hope for new treatment approaches.
Osteoplasty provides immediate and substantial pain relief for metastatic bone disease patients, often referred to as the 'Lazarus effect'. The procedure involves injecting bone cement into weakened bones, improving quality of life and allowing patients to resume daily activities.
A new study found that angiogenesis inhibitors, which starve tumors of their blood supply, can sometimes promote more invasive cancer growth and increase the incidence of metastases. Researchers call for further studies to determine if the drugs affect tumors in patients as they do in mouse models.
Researchers have precisely measured the impact of fat on cancer spread, finding that excessive dietary fat causes a significant increase in metastasizing tumor cells. The study used imaging and cell-counting tools to document changes in cancer cell membranes and count lipid-rich tumor cells in mice fed high-fat diets.
Researchers found that oxaliplatin combined with capecitabine provided a safe, well-tolerated, and effective treatment for patients with metastatic esophageal squamous cell cancer. The combination showed significant clinical benefits, including partial responses in 43.8% of patients and a median overall survival of 10.0 months.
Researchers identified guanylyl cyclase C as a molecular marker for metastatic colorectal cancer that can detect occult metastases in lymph nodes, improving risk stratification. About 13% of patients with pN0 colorectal cancer were found to be free of tumor cells, while 87% had results suggesting occult metastases.
The study investigates the anti-apoptotic effects of Astragalus saponin extract on human peritoneal mesothelial cells during peritoneal gastric cancer metastasis. The results show that gastric cancer cell supernatant induces apoptosis in mesothelial cells, while Astragalus injection can partly suppress this effect and regulate the expr...
Researchers at Thomas Jefferson University found a biomarker, guanylyl cyclase 2C (GUCY2C), that predicts disease recurrence in colorectal cancer. The study revealed that 87.5% of patients had positive GUCY2C expression and 20.9% developed recurrent disease.
Researchers at UC San Diego are developing new diagnostic tools to detect early-stage cancers using advanced imaging technologies. They aim to characterize tumor aggressiveness and monitor chemotherapy effectiveness, enabling more effective treatment decisions.
Researchers found that microRNA 182 is over-expressed in metastatic melanoma cell lines and tissues, leading to increased invasive capacity and metastatic potential. Inhibiting miRNA 182 may be an effective therapeutic strategy for metastatic melanoma.
A new study identifies Capn4 as a key molecule associated with liver cancer recurrence and metastasis after liver transplantation. The findings suggest that Capn4 expression is correlated with clinical outcomes and could be used as a prognostic marker for diagnosis.
Researchers at Tel Aviv University have refined breast cancer identification using a combination of MRI and ultrasound, allowing for earlier detection and personalized treatment. The new approach measures metabolism rates of cancer cells, helping determine which tumors will metastasize and how they should be treated.
Researchers investigate thalidomide for biochemical recurrence and adjuvant radiotherapy for improved survival, reducing metastases risk by 29%. Both treatment options show promise for patients with biochemically recurrent prostate cancer after surgery.
Researchers at Stanford University School of Medicine have discovered that metastatic cancer cells use a protein called lysyl oxidase (LOX) to target specific organs. By blocking LOX expression, the cells' migration and invasion can be prevented, offering a potential new approach to treating human disease.
A team of scientists at Princeton University has identified a long-sought gene, Metadherin, that is responsible for the aggressive behavior of poor-prognosis tumors and makes them resistant to chemotherapy. The discovery paves the way for new drugs to inhibit the gene's diabolical actions and may have significant health implications.
Researchers discovered abnormally high copy numbers of chromosomal region 8q22 in more than 30% of breast cancers, associated with shorter survival times. The metadherin gene (MTDH) was found to play a dual role in cancer metastasis and resistance to chemotherapy.
A research team at UC San Diego has identified a protein called versican that enhances metastasis by stimulating inflammatory cells. Versican is found in low amounts in normal lung epithelial cells but is upregulated in aggressive lung tumors, supporting the growth and spread of cancer.
Researchers at Tel Aviv University discovered that transfusions of 'young' blood –– blood stored for less than 9 days –– increased the odds of survival in animals with leukemia and breast cancer. Fresh blood may be a game-changer in cancer treatment, potentially improving survival rates.
A newly identified gene MACC1 has been found to be a powerful predictor of colon cancer metastasis. Patients with low MACC1 levels have a longer life expectancy compared to those with high MACC1 levels.
University of Texas Medical Branch researchers have identified a promising new target for colon cancer therapy by mapping the biochemical pathway critical to the spread of tumors. High levels of the enzyme Akt2 are found in association with other cancers, and its inhibition shows promise in stopping colon cancer's spread.
Researchers have identified a possible new therapeutic target for pancreatic cancer, the SINA gene, which regulates cell growth and oncogenesis. Inhibiting this gene's function may lead to novel anti-cancer therapies.
A team of researchers has identified the enzyme phospholipase Cγ1 as critical for breast cancer cell invasion and metastasis progression. Downregulating PLCγ1 expression can revert metastasis progression, suggesting a promising approach to cancer treatment.
Researchers at Albert Einstein College of Medicine have identified a protein called Menainv, which is present in invasive cells within a breast tumor. This protein enables tumor cells to become invasive and metastasize to other parts of the body.
Joan Massagué was honored with the inaugural AACR Distinguished Leadership Award in Breast Cancer Research for his work on transforming growth hormone factor-Beta and its role in metastasis. His research identified organ-specific metastatic characteristics that predict cancer cell spread.
A randomized trial found that systematic pelvic lymphadenectomy did not improve disease-free or overall survival in women with stage I endometrial cancer. Lymphadenectomy was associated with improved surgical staging and detection of disease spread to pelvic lymph nodes, but no therapeutic benefit.
Researchers at Mayo Clinic have discovered a 'two-faced' protein, p120 catenin, that promotes both tumor growth and metastasis in breast cancer. The protein acts like a tumor suppressor when bound to E-cadherin but becomes a tumor promoter when it's not.
Breast cancer cells closer to blood vessels are more aggressive and directed in their invasiveness, according to a new study. The research provides detail on how cancer cells invade surrounding tissue and reach blood vessels, offering insights into early stages of metastasis.
Researchers at Cincinnati Children's Hospital Medical Center have discovered a new molecular mechanism that coordinates cell identity and behavior in forming organs of embryos. The mechanism involves the interaction between two proteins, Wnt11 and Sfrp5, which regulate cell growth and development.
Researchers identified an 11-gene signature that separates responders from non-responders to FOLFIRI chemotherapy. The gene signature can predict treatment outcomes with 100% accuracy in a small sample size of 19 patients.
A study found that chest computed tomography (CT) can detect disease progression involving the lungs in high-risk patients with head and neck cancer. Indeterminate small solitary pulmonary nodules carry a higher risk of being malignant, highlighting the importance of aggressive evaluation and management.
Research reveals that blocking avb3 integrin leads to a5b1's increased trafficking and association with EGFR1, activating the Akt pathway and promoting random migration and invasive ability. This study sheds light on the mechanisms underlying metastatic movement in tumor cells.
Researchers discovered how the gene mda-9/syntenin interacts with signaling protein c-Src to promote metastasis in human melanoma cells. This interaction triggers a signaling cascade resulting in increased cancer cell motility, invasion and metastasis.
Research reveals nm23H1's role in predicting digestive system cancer, with MSI serving as an early biological marker and enhanced nm23H1 expression inhibiting metastasis. LOH appears in late stages, indicating higher malignancy.
A previously asymptomatic man developed a huge peritoneal mass after spontaneous rupture of hepatocellular carcinoma. The association between the metastatic tumor and viral infection, AFP level, or age was lacking due to few reported cases.
Patients who underwent both stereotactic radiosurgery and whole brain radiation experienced a 49% decline in learning and memory functioning, compared to 23% for those who received radiosurgery alone. Neurocognitive function was measured by recall of a list of 12 words after three attempts.
Research found that high alpha-catenin expression is associated with increased lymph node involvement and progressive disease in colorectal cancer. Alpha-catenin also showed distinct patterns in tumors of different colon locations, highlighting differences in molecular pathways between proximal and distal colon cancers.
Researchers found that a twice-weekly gemcitabine infusion schedule improved median survival time, disease-free survival time, and overall 1-year survival rate compared to previous studies. The study also showed that patients with reduced tumor markers had better prognosis.
The OB glue paste technique effectively establishes orthotopic transplantation models of human gastric cancer in nude mice. Observations showed that the success rate of transplantation, hepatic metastasis, and pulmonary metastasis rates were significantly high for both tumor strains.
Researchers have developed a new microbubble agent, Sonazoid, that enhances the sensitivity of contrast-enhanced intraoperative ultrasonography (CE-IOUS) for detecting occult liver lesions in patients with colorectal cancer. CE-IOUS using Sonazoid allows for longer imaging times and improved detection of metastases during hepatectomy.
Genetic testing identifies patients with advanced colorectal cancer who are likely to survive longer on cetuximab, a new standard of care for targeted therapies. Tumor cell analysis also reveals high levels of circulating cells before treatment as an indicator of disease aggressiveness.
Researchers at the Medical College of Wisconsin have developed a new synthetic form of the CXCL12 protein, which shows promise in inhibiting cancer cell migration and potentially stopping its spread. The discovery was made using a proprietary method to improve the detection of metastatic cancers.
Research finds that dense breast tissue promotes aggressive cancer cells, as breast cancer cells in denser surroundings step up their invasive activities. The study suggests a cellular mechanism linking human breast tissue density and tumor aggressiveness.
A study published in The American Journal of Pathology suggests that fibrocytes, cells involved in wound healing, can form premetastatic niches that facilitate cancer spread. Researchers found that injecting these cells into mice nearly doubled the rate of metastasis, a finding that could lead to new treatments.
A study published in the Journal of the American College of Surgeons found that elevated plasma DNA levels are a reliable marker of recurrent esophageal cancer. Plasma DNA levels rose before clinical evidence of recurrence in most patients, indicating its potential as a biomarker for disease monitoring.
A randomized controlled phase III trial found that everolimus significantly improves progression-free survival compared to placebo in patients with metastatic kidney cancer who have failed on sunitinib and sorafenib. The study also reported common adverse events, including stomatitis and fatigue.